These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 21077943

  • 1. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [Abstract] [Full Text] [Related]

  • 2. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Endocr J; 2010 Oct; 57(9):777-86. PubMed ID: 20683173
    [Abstract] [Full Text] [Related]

  • 3. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
    [Abstract] [Full Text] [Related]

  • 4. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
    [Abstract] [Full Text] [Related]

  • 5. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AF.
    Metabolism; 2011 Mar; 60(3):421-9. PubMed ID: 20423740
    [Abstract] [Full Text] [Related]

  • 6. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AF.
    Intern Med; 2010 Mar; 49(16):1717-25. PubMed ID: 20720348
    [Abstract] [Full Text] [Related]

  • 7. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P.
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [Abstract] [Full Text] [Related]

  • 8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 9. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Pharm Pharm Sci; 2010 Jun; 13(3):378-90. PubMed ID: 21092710
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
    Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P.
    Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 13. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Salvadeo SA.
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [Abstract] [Full Text] [Related]

  • 14. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
    Jacob S, Rabbia M, Meier MK, Hauptman J.
    Diabetes Obes Metab; 2009 Apr; 11(4):361-71. PubMed ID: 19207292
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [Abstract] [Full Text] [Related]

  • 17. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
    Berne C, Orlistat Swedish Type 2 diabetes Study Group.
    Diabet Med; 2005 May; 22(5):612-8. PubMed ID: 15842517
    [Abstract] [Full Text] [Related]

  • 18. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.
    Bougoulia M, Triantos A, Koliakos G.
    Hormones (Athens); 2006 May; 5(4):259-69. PubMed ID: 17178701
    [Abstract] [Full Text] [Related]

  • 19. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
    Derosa G, D'Angelo A, Romano D, Maffioli P.
    Drug Des Devel Ther; 2017 May; 11():1481-1488. PubMed ID: 28553078
    [Abstract] [Full Text] [Related]

  • 20. Exenatide versus glibenclamide in patients with diabetes.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.